Skip to content
DataLookout
Menu

PARAISONCT07174310

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 15 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 9 of 192 sites
  2. Notable Eligibility criteria expanded, about 10 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Site details revised at 7 of 192 sites
    • Publications: details revised at 1 of 1 entry
  3. Minor Trial sites expanded: 184 → 192 locationsv14
  4. Minor Trial sites expanded: 174 → 184 locationsv13
  5. Minor Trial sites expanded: 160 → 174 locationsv12
  6. Minor Trial sites expanded: 142 → 160 locationsv11
  7. Minor Trial sites expanded: 101 → 142 locationsv10
  8. Minor Trial sites expanded: 66 → 101 locationsv9
  9. Minor Study sites: 38 to 66v8
  10. Minor Study sites: 24 to 38v7
  11. Minor Study sites: 10 to 24v6
  12. Minor Study sites: 6 to 10
    • Primary completion date: Jul 27, 2029 to Jun 30, 2029
    • Study completion date: Jul 25, 2031 to Jun 30, 2031
    • Start date changed from estimate of Dec 31, 2025 to Nov 24, 2025
    v5
  13. Minor Study sites: 2 to 6v4
  14. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v3
  15. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score
Timeframe: Up to at least Week 104

Secondary (11)

Change From Baseline in Motor Function as Measured by the MDS-UPDRS Part III off Medication Score
Time to Worsening of Participants Motor Function as Reported by the Participant in the Presence of a Confirmed Motor Progression Event
Time to Meaningful Worsening in Clinician Global Impression of Change (CGI-C), Overall Disease Subscale
Time to increase in Levodopa Equivalent Daily Dose (LEDD)
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Show 6 moreShow less
Percentage of Participants With Adverse Events of Special Interest (AESI)
Percentage of Participants With Infusion Related Reactions (IRRs)
Percentage of Participants With Suicidal Ideation, as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Serum Concentration of Prasinezumab
Percentage of Participants With Anti-drug Antibodies (ADAs) Against Prasinezumab at Baseline
Percentage of Participants With ADAs Against Prasinezumab During the Study

Arms and interventions

PrasinezumabExperimental

Participants will receive Prasinezumab as an IV infusion in the double blind treatment period. Upon completion, eligible participants will enter into the Open Label Extension (OLE) phase.

PlaceboExperimental

Participants will receive placebo as an IV Infusion.

Drugs: Prasinezumab, Placebo

Sites

192 sites in 17 countries

United States 53, China 21, Germany 17, Italy 13, Spain 13, France 11, Poland 10, Brazil 8, Australia 7, Portugal 7, United Kingdom 7, South Korea 6, Taiwan 6, Austria 5, Canada 3, Denmark 3, Mexico 2